DAMORA THERAPEUTICS, INC. Increase (Decrease) in Income Taxes Receivable
DAMORA THERAPEUTICS, INC. (DMRA) reported Increase (Decrease) in Income Taxes Receivable of $856.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Cash Flow
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2021-11-04
- DAMORA THERAPEUTICS, INC. increase (decrease) in income taxes receivable for the quarter ending 2020-09-30 was $36.00K.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 9 month |
|---|---|---|---|
| 2021-09-30 | $856.00K 10-Q · filed 2021-11-04 | ||
| 2020-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $865.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $829.00K 10-Q · filed 2021-08-05 | ||
| 2019-09-30 | $804.00K 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |